Detailed information for compound 1456533

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 339.862 | Formula: C20H22ClN3
  • H donors: 1 H acceptors: 0 LogP: 5.53 Rotable bonds: 3
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCN(c1c2ccccc2[n+](c2c1[nH]c1c2cccc1)C)CC.[Cl-]
  • InChi: 1S/C20H21N3.ClH/c1-4-23(5-2)20-15-11-7-9-13-17(15)22(3)19-14-10-6-8-12-16(14)21-18(19)20;/h6-13H,4-5H2,1-3H3;1H
  • InChiKey: JOGNXYKWVHMCBD-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Toxoplasma gondii PAN domain-containing protein 0.0262136 0.5 0.5
Toxoplasma gondii PAN domain-containing protein 0.0262136 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (functional) = 1252 nM Antiplasmodial activity against chloroquine-resistant ring stage Plasmodium falciparum W2 infected in human red blood cells after 48 hrs ChEMBL. 21207937
IC50 (functional) = 1289 nM Antiplasmodial activity against chloroquine-sensitive, mefloquine-resistant ring stage Plasmodium falciparum D6 infected in human red blood cells after 48 hrs ChEMBL. 21207937
IC50 (functional) = 1773 nM Antiplasmodial activity against chloroquine and pyrimethamine-resistant ring stage Plasmodium falciparum V1/S infected in human red blood cells after 48 hrs ChEMBL. 21207937
IC50 (functional) = 2205 nM Antiplasmodial activity against chloroquine-sensitive ring stage Plasmodium falciparum 3D7 infected in human red blood cells after 48 hrs ChEMBL. 21207937
Ratio IC50 (functional) = 0.7 Resistance index, ratio of IC50 for chloroquine-resistant ring stage Plasmodium falciparum W2 to IC50 for chloroquine-sensitive ring stage Plasmodium falciparum 3D7 ChEMBL. 21207937

Phenotypes

Whole-cell/tissue/organism interactions

Species name Source Reference Is orphan
Plasmodium falciparum ChEMBL23 21207937

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.